Mary Lou Affronti
4PUBLICATIONS
3CO-AUTHORS

Get your video featured.

Get your video featured.
Publications (4)
Sort by Publication Date:
|Aug 15, 2025
Phase II randomized glioma study to evaluate efficacy and satisfaction of rolapitant plus ondansetron in preventing chemoradiation-induced nausea and vomiting.Mary Lou Affronti, Mallika P Patel, Erin K Severance
|May 10, 2024
MASCC 2023 Patient-Centered Antiemetic Guidelines and Education Statements: an evidence-based and consensus resource for patients.Mary Lou Affronti, Jiyeon Lee, Alex Molassiotis
|Sep 05, 2020
Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide".Mary Lou Affronti, James E Herndon, Mallika P Patel
|Aug 24, 2019
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.Mallika P Patel, Sarah Woodring, Dina M Randazzo
Pageof 1
